Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.30 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15968120 | 0.88 | CPB2 (0.37) | LMNACHRM2CHRM4CHRM5CHRM1 | |
| Trifluoroacetic Acid SCHEMBL16394222 | 0.88 | GABRR1 (0.32) | GABRR1LMNAMAPT | |
| SCHEMBL28712321 | 0.88 | LMNA (0.35) | LMNACHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL15968437 | 0.86 | CPB2 (0.40) | LMNACHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL17023644 | 0.83 | GABRR1 (0.40) | GABRR1GABBR2GABBR1 | |
| SCHEMBL27205315 | 0.83 | LMNA (0.35) | LMNACHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL29652036 | 0.83 | LMNA (0.42) | LMNACHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL445644 | 0.83 | LMNA (0.38) | LMNACHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL1148559 | 0.82 | LMNA (0.34) | LMNACHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL29029804 | 0.80 | CA2 (0.47) | LMNATSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140243286-A1 | BROMODOMAIN LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | COFERON, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| EP-1527070-B1 | AZOLE METHYLIDENE CYANIDE DERIVATIVES AND THEIR USE AS PROTEIN KINASE MODULATORS | MERCK SERONO SA (CH) | 2013-01-09 | — | — | EP | disclosed |
| US-7465736-B2 | Azole methylidene cyanide derivatives and their use as protein kinase modulators | LABORATOIRES SERONO S.A. (CH) | 2008-12-16 | — | — | US | disclosed |
| EP-1856048-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | Theravance, Inc. (US) | 2007-11-21 | — | — | EP | disclosed |
| US-20070185104-A1 | Benzoxazole acetonitriles | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2007-08-09 | — | — | US | disclosed |
| US-20070123530-A1 | Azole methylidene cyanide derivatives and their use as protein kinase modulators | MERCK SERONO SA (CH) | 2007-05-31 | — | — | US | disclosed |
| WO-2006098999-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2006-09-21 | — | — | WO | disclosed |
| WO-2006099091-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2006-09-21 | — | — | WO | disclosed |
| EP-1668004-A1 | BENZOXAZOLE ACETONITRILES | Applied Research Systems ARS Holding N.V. (AN) | 2006-06-14 | — | — | EP | disclosed |
| EP-1527070-A1 | AZOLE METHYLIDENE CYANIDE DERIVATIVES AND THEIR USE AS PROTEIN KINASE MODULATORS | Applied Research Systems ARS Holding N.V. (AN) | 2005-05-04 | — | — | EP | disclosed |
| WO-2005026159-A1 | BENZOXAZOLE ACETONITRILES | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2005-03-24 | — | — | WO | disclosed |
| WO-2003106455-A1 | AZOLE METHYLIDENE CYANIDE DERIVATIVES AND THEIR USE AS PROTEIN KINASE MODULATORS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123530-A1 | Azole methylidene cyanide derivatives and their use as protein kinase modulators | PRKACA, CSNK1A1, PRKACG | GABRR1 1352/4885LMNA 2319/4885CHRM2 1465/4885 |
| US-20140243286-A1 | BROMODOMAIN LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | BRDT, BRD4, BRD1 | GABRR1 1433/4885LMNA 1148/4885CHRM2 3119/4885 |
| US-20070185104-A1 | Benzoxazole acetonitriles | PKD1, PC, GPR119 | GABRR1 1616/4885LMNA 629/4885CHRM2 2274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.